Target intelligence / Profile preview

Dectin-1 receptor (Dectin-1)

Target
Dectin-1
Molecular classification
Receptor, Pattern recognition receptor (PRR), C-type lectin-like receptor (CLR)
01

Overview

Dectin‑1, encoded by the CLEC7A gene, is a type II transmembrane protein belonging to the C-type lectin-like receptor family. It functions primarily as a pattern-recognition receptor for β-(1→3)/(1→6)-linked glucans found in fungal cell walls but can also recognize endogenous ligands. Structurally, it features an extracellular carbohydrate-recognition domain that binds glucans independently of calcium ions and an intracellular tail containing a hemITAM motif crucial for signal transduction. Upon ligand binding—such as during fungal infection—Dectin‑1 triggers phagocytosis and induces pro-inflammatory cytokines through Syk kinase-dependent pathways. It is highly expressed on myeloid cells including monocytes/macrophages, dendritic cells, neutrophils, and some lymphoid subsets. Beyond host defense against fungi, Dectin‑1 has emerging roles in anti-tumor immunity by recognizing tumor-associated glycans; it also participates in inflammatory diseases and can have both protective or pathogenic effects depending on context.[1][2][3]

Other names
β-glucan receptorCLEC7AC-type lectin domain family 7 member A
02

Mechanism of action

Drugs or biologicals targeting Dectin‑1 typically act by: - Agonism with β-glucan ligands to stimulate innate immune responses such as cytokine release and phagocytosis. - Modulation of downstream signaling pathways including Syk kinase activation via its hemITAM motif.

03

Biological functions

Innate immune responsePathogen recognition (especially fungal β-glucans)Signal transduction leading to cytokine productionPhagocytosis induction
04

Disease associations

Infection (notably fungal infections)InflammationCancer/anti-tumor immunityAutoimmunity and allergy (context-dependent roles)
05

Safety considerations

Overactivation may contribute to excessive inflammation or autoimmunity in susceptible individuals.Potential risk of exacerbating allergic responses depending on context.
06

Interacting drugs

There are no widely approved drugs that directly target Dectin‑1 in clinical use. However, several experimental agents modulate its activity or use β-glucans as agonists for immunomodulation.
07

Biomarkers

Expression levels of Dectin‑1 on monocytes/macrophages can serve as biomarkers for innate immune competence or response to certain infections/cancers.Cytokines induced downstream of Dectin‑1 activation may also serve as pharmacodynamic markers.

Beyond the preview

Go deeper on Dectin-1 receptor (Dectin-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dectin-1 receptor (Dectin-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call